RxDoctor Payments Data

Sureshkumar Muttath, MD

Internal Medicine · Riverdale, MDNPI 1275599458

Payments from drug & device makers

$10,486in general payments, 2019–2025

Across 622 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$756
  • AbbVie$642
  • Merck$579
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$10,28698%
  • Education$190%
  • Other$1812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,486 in reported general payments places this provider in the 90th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$870,450
Medicare patients
390
Services billed
16,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol83$111,768
JardianceEmpagliflozin87$105,230
OzempicSemaglutide84$103,110
CreonLipase/Protease/Amylase11$66,477
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$65,538
EliquisApixaban44$62,347
TrulicityDulaglutide26$50,151
XareltoRivaroxaban47$45,162
KerendiaFinerenone33$37,309
EntrestoSacubitril/Valsartan33$35,808
LinzessLinaclotide43$35,742
JanuviaSitagliptin Phosphate18$23,950
Tresiba Flextouch U-100Insulin Degludec34$19,881
TradjentaLinagliptin18$14,714
OxycontinOxycodone Hcl12$14,547

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$323$119,944105 claims
AstraZenecaFarxiga$1,128$111,76883 claims
Novo NordiskOzempic$1,287$103,11084 claims
AbbVieCreon, Linzess$642$102,21954 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Shingrix, Arnuity Ellipta$573$88,271133 claims
PfizerEliquis$1,006$62,34744 claims
Lilly USA, LLCTrulicity$756$50,15126 claims
Johnson & JohnsonXarelto$267$45,16247 claims
BayerKerendia$160$37,30933 claims
NovartisEntresto$198$35,80833 claims
MerckJanuvia$579$23,95018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Riverdale

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →